Ophthalmic drugs monograph
This article was originally published in The Tan Sheet
Executive SummaryFDA is updating its OTC ophthalmic drug products final monograph "to be consistent with" USP name change for active ingredient hydroxypropyl methylcellulose that took effect in September 2002, agency says in 1June 3 Federal Register notice. New name for active ingredient is hypromellose, FDA notes. Manufacturers of OTC ophthalmic drug products will have until Sept. 1 to implement labeling changes, agency adds...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.